U.S., Dec. 25 -- ClinicalTrials.gov registry received information related to the study (NCT07301424) titled 'Subcutaneous Blinatumomab Plus Ponatinib for BCR-ABL+ B-ALL' on Dec. 12.
Brief Summary: B-cell acute lymphoblastic leukemia (B-ALL) is an aggressive blood cancer; about 30% of B-ALL cases in adults have a mutation called BCR-ABL that drives the disease.
Blinatumomab is an antibody drug that targets B-ALL cells and helps the immune system to kill them. It is usually given intravenously, but a newer formulation can be given under the skin. Ponatinib is a drug, taken by mouth, that targets and kills leukemia cells that have the BCR-ABL mutation.
The goal of this clinical trial is to test the effectiveness of treating patients with BC...